Carboplatin dosing based on measurement of renal function - Experience at the Peter MacCallum Cancer Institute

被引:45
|
作者
Millward, MJ [1 ]
Webster, LK [1 ]
Toner, GC [1 ]
Bishop, JF [1 ]
Rischin, D [1 ]
Stokes, KH [1 ]
Johnston, VK [1 ]
Hicks, R [1 ]
机构
[1] PETER MACCALLUM CANC INST,DIV HAEMATOL & MED ONCOL,MELBOURNE,VIC 3000,AUSTRALIA
来源
关键词
carboplatin; renal function; cancer; Peter MacCallum Cancer Institute;
D O I
10.1111/j.1445-5994.1996.tb01925.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Carboplatin is used in treating many types of cancer. Because renal excretion is the major variable determining the pharmacokinetics of this drug, a dosing formula based on glomerular filtration rate (GFR) has been proposed and is being increasingly used in carboplatin dosing. This method of dosing is critically dependent on accurate measurement of GFR. Aims: To report the experience at a single major oncology centre of carboplatin dosing based on GFR, and comparisons of different methods of measuring renal function for use in this dosing method. Methods: An initial group of patients (n=24) was studied where GFR was measured by Cr(51)EDTA clearance and compared to Tc(99m)DTPA clearance, measured 24 hour urine creatinine clearance and the Cockcroft and Gault formula. The carboplatin area under the plasma concentration versus time curve (AUC) was calculated using total platinum measured in a single blood sample assayed by flameless atomic absorption spectrophotometry. A subsequent patient group (n = 16) was then studied using Tc(99m)DTPA clearance to measure GFR. Results: Carboplatin dosing using Cr(51)EDTA clearance to measure GFR was accurate (<25% difference between planned and measured AUC) in 87% of samples. Estimation of renal function using the Cockcroft and Gault formula correlated with Cr(51)EDTA clearance only in patients with GFR <100 mL/minute. The measured 24 hour urine creatinine clearance did not correlate with Cr(51)EDTA clearance. Using Tc(99m)DTPA clearance to measure GFR, carboplatin dosing was accurate in 81% of samples. Across a GFR range of 42-239 mL/minute, the Cr(51)EDTA and Tc(99m)DTPA clearances were closely correlated (r = 0.98, slope of regression line = 1.02). Conclusions: Carboplatin dosing using a pharmacological formula based on GFR produces accurate targeting of the carboplatin AUC. Tc(99m)DTPA clearance can be used to measure GFR instead of Cr(51)EDTA clearance, which is both more convenient and has potential cost savings. Estimates of renal function using the Cockcroft and Gault formula or measured 24 hour creatinine clearance are insufficiently accurate to use for carboplatin dosing.
引用
收藏
页码:372 / 379
页数:8
相关论文
共 50 条
  • [1] Paranasal sinus tumors: Peter MacCallum Cancer Institute experience
    Porceddu, S
    Martin, J
    Shanker, G
    Weih, L
    Russell, C
    Rischin, D
    Corry, J
    Peters, L
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2004, 26 (04): : 322 - 330
  • [2] RADIATION-THERAPY OF GLOTTIC CARCINOMA - MACCALLUM,PETER CANCER INSTITUTE EXPERIENCE
    GUINEY, M
    SMITH, J
    HUGHES, P
    NARAYAN, K
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1992, 62 (08): : 622 - 627
  • [3] Recreating pastoral care at Peter MacCallum Cancer Institute
    Dawes, D
    [J]. PSYCHO-ONCOLOGY, 2000, 9 (05) : S61 - S61
  • [4] High-dose therapy and autologous transplantation for lymphoma: The Peter MacCallum Cancer Institute experience
    Dowling, AJ
    Prince, HM
    Wirth, A
    Wolf, M
    Januszewicz, EH
    Juneja, S
    Seymour, JF
    Gates, P
    Smith, JG
    [J]. INTERNAL MEDICINE JOURNAL, 2001, 31 (05) : 279 - 289
  • [5] Cancer prognosis methodology for cervical cancer to be used by Peter MacCallum Cancer Institute
    Bevinakoppa, S
    [J]. ANZIIS 2001: PROCEEDINGS OF THE SEVENTH AUSTRALIAN AND NEW ZEALAND INTELLIGENT INFORMATION SYSTEMS CONFERENCE, 2001, : 25 - 30
  • [6] Investigating current practices in renal function measurement and carboplatin dosing in children with cancer - a UK perspective
    Roberts, Eve
    Mogg, Jasper A. W.
    Barnfield, Mark
    Veal, Gareth J.
    [J]. PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2020, 37 (03) : 235 - 244
  • [7] Tonsillar cancer: The Peter MacCallum experience with unilateral and bilateral irradiation
    Liu, Chen
    Dutu, Gaelle
    Peters, Lester J.
    Rischin, Danny
    Corry, June
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2014, 36 (03): : 317 - 322
  • [8] TREATMENT OF PEDIATRIC GENITOURINARY MALIGNANCY WITH INTERSTITIAL BRACHYTHERAPY - PETER-MACCALLUM-CANCER-INSTITUTE EXPERIENCE WITH 4 CASES
    LEUNG, S
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (02): : 393 - 398
  • [9] Squamous cell carcinoma of the lip: A retrospective review of the Peter MacCallum Cancer Institute experience 1979-88
    McCombe, D
    MacGill, K
    Ainslie, J
    Beresford, J
    Matthews, J
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 2000, 70 (05): : 358 - 361
  • [10] HYPOPHARYNX CARCINOMA - REVIEW OF THE PETER MACCALLUM CANCER CENTRE (PMCC) EXPERIENCE
    Germain, F.
    Brennan, S.
    Corry, J.
    Herschtal, A.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2009, 92 : S62 - S62